Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
3,242
Total Claims
$13.5M
Drug Cost
335
Beneficiaries
$40K
Cost/Patient
Risk Score Breakdown 11/100
Score components are additive. Read full methodology
Peer Comparison vs. 8,541 Hematology-Oncology providers
-71%
Opioid rate vs peers
1.9% vs 6.3% avg
+196%
Cost per patient vs peers
$40K vs $14K avg
Opioid Prescribing
1.9%
Opioid Rate
60
Opioid Claims
$942
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 0 claims · $0
Generic: 2,256 claims · $527K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Lenalidomide | 323 | $5.2M |
| Ibrutinib | 128 | $1.7M |
| Pomalidomide | 64 | $1.4M |
| Venetoclax | 129 | $1.3M |
| Ruxolitinib Phosphate | 76 | $1.3M |
| Dasatinib | 47 | $572K |
| Eltrombopag Olamine | 25 | $341K |
| Lenalidomide | 21 | $288K |
| Bosutinib | 11 | $227K |
| Decitabine/Cedazuridine | 18 | $145K |
| Nilotinib Hcl | 14 | $142K |
| Imatinib Mesylate | 61 | $126K |
| Zanubrutinib | 17 | $121K |
| Apixaban | 63 | $47K |
| Acyclovir | 715 | $13K |
Prescribing Profile
Patient Profile
74
Avg Age
45%
Female
2.33
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data